GIPR antagonist peptideGLP-1 Agonists
AT7687
A first-in-class GIP receptor antagonist peptide by Antag Therapeutics. Phase 1 completed, Phase 2a expected mid-2026. Combined with liraglutide showed 16.3% body weight reduction, 52% insulin reduction, and 43% triglyceride reduction in primates.
GIPR-antagonistweight-lossinsulin-reductiontriglyceride-reduction
3D Structure
3D Structure
Lab Tested
No
Harmful Ingredients
0
Contaminants
None
Tested Purity
--
Batch Consistency
No batch data
Mass Spec Profile
No mass spec data
Batch Info
Latest Batch—
Total Tests0
Unique Vendors0
Vendor Comparison
No vendor data yet
Analysis Summary
Purity Standard
No purity dataLab Reports
0 reports on file
Summary
A first-in-class GIP receptor antagonist peptide by Antag Therapeutics. Phase 1 completed, Phase 2a expected mid-2026. Combined with liraglutide showed 16.3% body weight reduction, 52% insulin reducti…